Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sponsors May Race For Rare Pediatric Voucher Designations As Deadline Nears

Executive Summary

US FDA program's new 2020 sunset could create a bolus of designation requests to ensure they can still get a voucher if it ends.

Advertisement

Related Content

Capricor Eyes RMAT Designation Based On Interim Phase II Data
Emflaza's 505(b)(2) Pathway Review: Rare, But With Precedent
Voucher Does Not Guarantee A Priority Review, FDA Says
Priority Review Voucher Program For Rare Pediatric Diseases Extended As FDA Lowers Fee
Duchenne Surprise: Sarepta Prices Exondys 51 Below Expectations
Tracking The Priority Review Vouchers
Priority Review Vouchers Appear To Be Dropping In Price
Orphan Designation Requests To Get Slower Reviews
Review Voucher Program For Rare Pediatric Diseases Should Not Be Reauthorized, US FDA Says
Vimizim Voucher A Result Of BioMarin’s Late Request, FDA Flexibility

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS119701

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel